Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Actas Dermo-Sifiliograficas|May 3, 2014
Management of refractory telaprevir-induced dermatitis using oral corticosteroidsJ Garcias-Ladaria, A Pérez-Ferriols, P Ortega-García, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|January 8, 2015
Characterization of blood flow in the mouse dorsal spinal venous system before and after dorsal spinal vein occlusionMatthew J Farrar, Jonathan D Rubin, Darcy M Diago, et al.
Gastroenterologia Y Hepatologia|January 12, 1999
[Focal nodular liver hyperplasia of atypical presentation]S Pamos, M Luján, V García, et al.
Revista Espanola De Enfermedades Digestivas|March 1, 1990
[Physical exercise and gastric acid secretion]P Canelles, M Diago, A Tomé, et al.
Gastroenterologia Y Hepatologia|November 11, 1998
[Prevalence of anti-hepatitis A in patients with chronic liver disease]M Diago, M Luján, V García, et al.
Journal of Hepatology|August 1, 1996
Intrafamily transmission of hepatitis C virus: sexual and non-sexual contactsM Diago, R Zapater, C Tuset, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 1, 1997
Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis CA Castro, E Carballo, A Domínguez, et al.
Journal of Viral Hepatitis|February 16, 2006
Epidemiological, biological and histological characterization of patients with indeterminate third-generation recombinant immunoblot assay antibody results for hepatitis C virusM Ríos, M Diago, P Rivera, et al.
Revista Espanola De Enfermedades Digestivas|August 3, 2001
Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferonM Diago, M Luján, D Valeros, et al.
Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2003
Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4J M Sánchez-Tapias, J Crespo, M Diago, et al.
Pageof 5